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Background: Preoperative anemia in surgical patients has been linked to increased rates of 
allogeneic blood transfusion (ABT) and associated adverse patient outcomes such as prolonged 
ventilation in intensive care, increased length of hospital stay, and infections. We conducted a 
multifaceted implementation for orthopedic surgeons to improve preoperative patient assessment 
of anemia and iron deficiency to reduce perioperative blood transfusions.
Materials and methods: Using a before-and-after study design of independent samples, we 
recruited a convenience sample of surgeons who performed primary total hip arthroplasty at 1 
Australian private hospital. Our implementation intervention consisted of: executive support, 
interactive education, and peer-to-peer support to encourage adherence to the National Blood 
Authority’s Patient Blood Management Program (PBMP) guidelines. We also used monthly 
reminders, e-learning access, and posters. Pre and post medical record audits evaluated preop-
erative blood tests, preoperative anemia, and number of blood units transfused between day of 
surgery until discharge. The primary outcome was an increase in the proportion of patients with 
preoperative blood tests undertaken prior to total hip arthroplasty surgery as recommended by 
the PBMP guidelines.
Results: Audits from 239 pre- and 263 postimplementation patients from 3 surgeons were 
conducted. Our primary outcome showed a significantly increased proportion of patients who 
had all the required preoperative tests postimplementation (0% to 94.6%; P<0.0001). Admin-
istration of ABT significantly decreased (pre: 9.2%, n=22; post: 2.3%, n=6; P=0.001) as well 
as the standard 2 blood units transfused (pre: 73%, n=16; post:17%, n=1; P=0.022). The time 
between preoperative tests and day of surgery increased from 16 to 20 days (P<0.0001), allow-
ing more time for physician’s review of test results.
Conclusion: Our results demonstrated successful implementation of a targeted PBMP to 
improve preoperative assessment to diagnose and treat anemia and/or iron deficiency prior to 
orthopedic surgery. This avoided unnecessary ABT and therefore mitigated potential risk to 
the patient.
Keywords: anemia, allogeneic blood transfusion, iron deficiency, patient blood management, 
clinician behavior change, implementation research
Introduction
Preoperative anemia (hemoglobin [Hb] level of <130 g/L in men and <120 g/L in 
women)1,2 is present in approximately 30% of noncardiac surgical patients.3 It is asso-
ciated with increased allogeneic blood transfusion (ABT) rates, prolonged ventilation 
in intensive care, increased length of hospital stay, and infection.3–8 The prevalence of 
preoperative anemia increases with age,9 contributing to significant morbidity and poor 
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functional outcomes for older surgical patients in particular.6 
Absolute or functional iron deficiency (ferritin level of <100 
µg/L or between 100 µg/L and 299 µg/L if the transferrin 
saturation is <20%)10–12 and/or chronic inflammation are the 
most common causes of preoperative anemia.13
There is a plethora of literature that describes the inci-
dence of anemia in preoperative surgical patients as well as 
the link between anemia, ABT, and adverse outcomes.4,5,7,14 
Current transfusion practices include liberal or restrictive 
strategies based on thresholds of hemoglobin of 10 g/dL 
or 8 g/dL, respectively. Liberal strategies have not been 
found to be superior to restrictive strategies,15–17 and some 
have shown worse patient outcomes, such as cardiac events, 
pneumonia, thromboembolism, and infections.18,19 Therefore, 
restrictive strategies have been the recommended approach 
when a blood transfusion is necessary to treat anemia, and 
as a conservative measure in the use and management of 
blood products.
The need to conserve blood and reduce waste has been 
driven by the increasing aging population, cost of “fresh” 
blood products, and adverse events associated with transfu-
sions.8 In 2012 in Australia, the National Safety and Quality 
Health Service Standards were released.20 Standard 7 (Blood 
and Blood Products) specifically advocated for a safe and 
efficient use of blood products as a scarce resource. In addi-
tion, the new Australian Patient Blood Management (PBM) 
Guidelines (Module 2: Perioperative) was also published in 
2012 containing 22 evidence-based recommendations and 
20 practice points supporting the new standard of care to 
identify, evaluate, and manage preoperative anemia.21 The 
recommendation of the PBM guidelines is to perform preop-
erative tests comprised of: a full blood count, full iron studies 
(including ferritin), C-reactive protein, and renal function 
studies (including urea, creatinine, and electrolytes). These 
tests form the baseline assessment for perioperative care in 
which abnormal blood results should encourage physicians’ 
review and treatment in the case of anemia, iron deficiency, 
and renal impairment.
The impetus for implementing a Patient Blood Manage-
ment Program (PBMP) in our study was contributed to by 2 
additional issues. First, a 2013 hospital-wide accreditation 
recommended that patients with low hemoglobin should 
be identified earlier and managed appropriately. Second, a 
2012 retrospective medical record audit of primary total hip 
arthroplasty patients (n=383) conducted between July and 
December 2011 indicated 21% (n=79) of patients received an 
ABT, of whom 35% (n=28) of the 79 patients were clinically 
anemic preoperatively resulting in 87% (n=69) of patients 
with 2 or more units of ABT. The argument for a PBMP is 
compelling and is advantageous for patients and hospitals 
alike.22 However, the effectiveness of achieving a change in 
long-standing practices involves changing perception and 
long-held behavior by clinicians.23 Our implementation at 
an Australian private hospital aimed to improve adherence 
of orthopedic surgeons to the PBM guidelines to evaluate 
and manage preoperative anemia 0–28 days prior to surgery, 
thereby increasing the proportion of patients with a complete 
set of preoperative tests prior to total hip arthroplasty surgery.
Materials and methods
Using a before-and-after design with independent samples, 
this study was conducted at 1 private metropolitan hospital in 
Sydney, Australia. This hospital was ideally placed to adopt 
a PBMP as it was a center that performed in excess of 2,000 
total joint arthroplasties per year.
Sampling and recruitment
Eligible surgeons were those who performed >100 primary 
unilateral total hip arthroplasties each year as they were 
regarded to represent the patient population due to their 
high volume of surgical patients. Eligible surgeons and their 
usual anesthetists were invited by e-mail to attend a 1 hour 
study launch and education session presented by a specialist 
physician and the principal investigator. The launch outlined 
key messages of the PBMP (Box 1) and was convened by a 
specialist nephrologist with a special interest in the PBMP 
and was co-hosted by the Hospital Chief Executive. Fol-
lowing this presentation, the surgeons were visited in their 
consulting rooms by the principal investigator who provided 
the information sheet and asked for their signed consent to 
participate in the study.
The medical records of patients who had undergone a 
primary unilateral total hip arthroplasty procedure under one 
of the eligible participating surgeons were included. Medical 
records of patients who had undergone emergency surgery, 
bilateral or revision surgery, and those who had previously 
had surgery on the other hip during our preimplementation 
phase were excluded from the study. Patient consent was not 
required as this retrospective audit was considered to be part 
of standard hospital reporting practices. Ethical approval was 
obtained from St Vincent’s Hospital, Darlinghurst Human 
Research Ethics Committee.
Intervention
The intervention was conducted from October 2014 until 
June 2015 (Box 2) and entailed the following: 1) executive 
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support from the Chief Executive Officer of the hospital 
who launched the project; 2) 1 interactive education session 
for surgeons/anesthetists and 1 for nurses conducted by the 
principal investigator focusing on outlining the key mes-
sages from the PBM guidelines; 3) peer-to-peer support to 
surgeons via telephone by the specialist physician; 4) 1 audit 
and feedback conducted midway through the implementa-
tion to maintain and encourage guideline compliance; and 
5) monthly e-mail reminders and relevant articles sent to 
participating surgeons (Box 3). Other steps of the implemen-
tation included placement of Blood Watch posters, which 
is a state-wide transfusion practice improvement program 
supported by the Department of Health.24
The implementation targeted orthopedic surgeons. How-
ever, ward and preadmission clinic nurses were also invited 
to attend 1 education session with the rationale that they 
Box 1 National Blood Authority, Australia, Patient Blood Management Guidelines: Module 2 – Perioperative 2012
Preoperative phase: All patients to have preoperative full blood count to examine hemoglobin levels, full iron tests (including ferritin and 
transferrin saturation), C-reactive protein, and renal function tests (urea and creatinine) added to their standard preoperative blood tests up to 
28 days preoperatively.
Anemia (hemoglobin level of <130 g/L in men and <120 g/L in women) and low iron stores (ferritin level of <100 µg/L) to be treated with iron 
replacement prior to surgery (either oral iron in divided daily doses, or intravenous iron if oral iron not tolerated or effective or where rapid 
iron repletion is required ie, <2 months to nondeferrable surgery) as indicated by the National Blood Authority’s preoperative algorithm.
As serum ferritin is an acute-phase reactant, it is important to examine both ferritin and transferrin saturation levels to determine the level of 
iron stores.
Postoperative phase: Patients are not to receive a blood transfusion when the hemoglobin level is ≥100 g/L in the postoperative period from 
day of surgery until discharge on day 5–7 of the acute postoperative period. 
Patients with postoperative anemia should be assessed based on the patient’s clinical status and not on a hemoglobin ‘trigger’ alone. If a 
transfusion is deemed necessary, then 1 unit of blood is to be administered and the patient reassessed to examine response prior to further 
transfusion.
Note: Data from the National Blood Authority.21
Box 2 PBMP implementation
Executive support
The Chief Executive Officer of the hospital opened the project launch.
Interactive education
A specialist physician and the CEO of the hospital launched the project and presented the key PBMP messages to surgeons during a 30-minute 
presentation.
Orthopedic ward nurses and pre-admission clinic nurses were also informed of the implementation project and attended a single 15-minute 
educational session outlining PBM aims and outcome measures. Nursing education was supported by Blood Safe e-learning module – Patient 
Blood Management located on the hospital’s intranet.
Peer to peer support
Specialist physician was available by telephone call or email to provide expert clinical advice concerning blood results and treatment.
Principal investigator made daily visits to pre-admission staff to encourage interpretation of blood results emphasising anemia and iron 
deficiency markers and encouragement to contact the relevant surgeon.
Email and poster reminders
Official National Blood Authority posters were placed in the stairwell and treatment rooms. These posters were changed monthly and 
communicated key messages such as single unit transfusion and dispelling myths about blood safety, improved healing and no associated cost 
with blood transfusion.
Monthly short targeted emails were sent to participating surgeons to remind them of the key points from the launch (Box 3), guidelines and 
relevant articles.
Audit feedback mechanism
Half way through the implementation phase an audit and feedback was conducted and reported back to the surgeons.
Abbreviations: CEO, Chief Executive Officer; PBMP, Patient Blood Management Program.
 
Jo
ur
na
l o
f B
lo
od
 M
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
2.
14
8.
22
8.
60
 o
n 
27
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Blood Medicine 2018:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
86
Morgan et al
could guide, influence, and prompt surgeon and/or anesthetist 
compliance with guidelines by instigating preoperative iron 
replacement when necessary. While anesthetists also attended 
the initial education session, there was no further face-to-face 
contact with anesthetists.
Data collection
Retrospective audits of medical records from patients of 
consenting orthopedic surgeons were performed between July 
to December 2012 and July to December 2015 for the pre-
implementation and postimplementation audit, respectively. 
Patient names were obtained from preadmission clinic. Both 
medical record audits used identical tools and methods and 
were collected by the primary researcher. Audit data provided 
to surgeons were deidentified and aggregated.
Outcome measures
The primary outcome measure was the number of patients 
who 0–28 days prior to total hip arthroplasty surgery had 
all of the following preoperative blood tests: 1) full blood 
count, 2) full iron studies, including ferritin and transferrin 
saturation, 3) C-reactive protein, 4) renal function studies, 
including urea, creatinine, and electrolytes.
Secondary outcome measures were 1) the number of 
ABTs administered between the day of surgery and postop-
erative day 7 (or day of discharge – whichever came first), 
2) the time between ordering the preoperative tests and day 
of surgery (in days), 3) the level of anemia as defined by the 
World Health Organization definition (hemoglobin <130 g/L 
in men and <120 g/L in women), 4) iron deficiency defined as 
a ferritin <100 µg per liter or between 100 and 299 µg per liter 
if the transferrin saturation is <20% in the 0–28 days prior to 
day of surgery, 5) the number of preoperative iron infusions 
related to low ferritin and transferrin saturation, and 6) the 
administration of tranexamic acid (antifibrinolytic proven to 
reduce a patient’s perioperative blood loss).
Instrument
The following data were collected using a piloted form: 1) 
patient characteristics; 2) laboratory results; 3) clinical treat-
ment; 4) surgery details; 5) and postoperative treatment. In 
the patient characteristics section age, gender, admission, 
and discharge dates were recorded. Preoperative laboratory 
results were obtained from both the medical records and 
access to the online pathology service. The number of days 
between the preoperative tests and the booked surgery date 
was recorded. The preoperative tests comprised: full blood 
count, full iron studies (including ferritin and transferrin 
saturation), C-reactive protein, and renal function studies 
(including urea, creatinine, and electrolytes count). In the 
clinical treatment section of the instrument, we recorded the 
administration of a preoperative iron infusion. Surgery details 
collected were surgery date, the use of tranexamic acid (Yes/
No), and the American Society of Anesthesiologists score 
(ASA) completed by the anesthetist prior to induction.25 
Finally, the postoperative treatment data collected included 
the number of ABT units and, where relevant, the postopera-
tive day of transfusion.
Data analysis
Data were analyzed using SPSS version (IBM SPSS Statistics 
23, IBM Corporation, Armonk, NY, USA). The proportion 
of patients who had all 4 preoperative blood tests performed 
was calculated. The categorical and continuous data were 
summarized as descriptive statistics. Pre- and postimple-
mentation differences for patient characteristics, preoperative 
blood tests, anemic patients with ABT and use of tranexamic 
acid were examined using χ2 tests or Fisher’s exact test as 
appropriate. Independent sample t-test was used to examine 
mean differences of time between the ordering day of the 
preoperative tests and the day of surgery in the pre- and 
postimplementation groups. The P-value for the statistical 
significance was set at <0.05.
Box 3 Content of monthly reminder emails
1. Blood tests including full blood count, full iron tests, C-reactive protein, electrolytes/urea/creatinine should preferably be performed at least 
28 days pre-op. Please “copy” the results to the general practitioner, whatever physician is involved in the patient’s care, and the hospital’s 
preadmission clinic.
2. It is never too late – ideally iron infusions should be administered at least 3 weeks prior to surgery but may provide clinically significant 
benefit even if administered in the days prior to surgery.
3. Consider referral to the preadmission clinic at least 4 weeks pre-op whenever possible.
4. Patients with stable cardiovascular disease do not necessarily need to have their hemoglobin “topped up” above 80 g/L. In fact, they may 
benefit more from an iron infusion if clinically indicated.
5. In the rare instances where a blood transfusion is considered absolutely necessary, transfuse a single unit and repeat the full blood count.
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Results
All 3 eligible orthopedic surgeons agreed to participate in the 
study. A total of 239 medical records of patients undergoing 
primary total hip arthroplasty were audited for the preimple-
mentation phase and 263 for the postimplementation phase. 
All patients’ medical records from participating surgeons in 
the preimplementation group met the inclusion criteria. In the 
postimplementation phase, there were 2 patients who were 
excluded: 1 was an emergency fracture and the other patient 
had a unilateral hip and knee replacement concurrently. 
There were 64% (n=154) females in the preimplementation 
phase and 58% (n=151) in the postimplementation phase. 
The most common age group was 61–80 years old, with 
61% (n=145) in the preimplementation and 70%, (n=183) in 
the postimplementation phase (Table 1). The overall health 
status of patients was inferred by the ASA score. The ASA 
showed that the highest rating assessment was ASA 2 (pre: 
47%, n=113; post: 40%, n=105; P=0.19) indicating that 
most patients in both groups were relatively healthy. The 
only significant difference between groups was for the ASA 
3 score (ie, severe systemic disease), but this was seen only 
in 11% of patients from the preimplementation and 20% of 
patients from the postimplementation (P=0.003; Table 1).
Primary outcome
There was a significant increase in the number of patients 
who 0–28 days prior to total hip arthroplasty surgery had 
all preoperative tests performed following our intervention 
(95%; n=247, P<0.0001), compared to none in the preim-
plementation group (Table 2). Of these preoperative tests, 
over 98% of patients in both pre- and postimplementation 
group had a full blood count and renal function studies 
performed. However, significant increases were observed 
from pre- (n=1, 0.4%) to postimplementation (n=254, 
97%) in the number of patients who had full iron stud-
ies (P<0.0001) and a C-reactive protein test (pre: n=132, 
55%; post: n=245, 94%; P<0.0001). Time (days) between 
the preoperative tests and the date of surgery significantly 
increased from 16 to 20 days following the implementation 
(P<0.0001, Table 2).
Table 1 Patient demographics
Demographics Preimplementation 
(n=239) n (%)
Postimplementation 
(n=261) n (%)
P-value*
Gender
Female 154 (64) 151 (58) 0.132
Male 85 (36) 110 (42)
Age (years)
0–40 3 (1.2) 5 (1.9) 0.402
41–60 72 (30) 50 (19)
61–80 145 (61) 183 (70)
81+ 19 (7.9) 23 (8.8)
ASAa
Healthy person 47 (20) 35 (13) 0.87
Mild systemic disease 113 (47) 105 (40) 0.19
Severe systemic disease 26 (11) 51 (20) 0.003*
Severe systemic disease that is a constant threat to life 0 3 (1.1) 0.25b
Not recorded 53 (22) 67 (26)
Notes: aPhysical status system by ASA, bFisher’s exact test, *P-value significant <0.05.
Abbreviation: ASA, American Society of Anesthesiologists.
Table 2 Patient’s preoperative tests and time completed
Preoperative tests Preimplementation  
(n=239) n (%)
Postimplementation  
(n=261) n (%)
P-value*
Full blood count 238 (99.5) 260 (99.6) 0.999
Full iron studies (ferritin and transferrin saturation) 1 (0.4) 254 (97) <0.0001*
C-reactive protein 132 (55) 245 (94) <0.0001*
Renal function studies (urea, creatinine, and electrolytes) 238 (99.5) 258 (98.8) 0.625a
All above preoperative tests completed 0 247 (95) <0.0001*
Time (days) preoperative blood sample obtained to day of 
surgery (mean)
16 (days) 20 (days) <0.0001*
Notes: *P-value significant <0.05; aFisher’s exact test.
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Secondary outcomes
The levels of preoperative anemia were not significantly 
different between the pre- and postimplementation group 
(P=0.224) (Table 3). However, there was a significant 
decrease of ABT postoperatively (pre: 9.2%, n=22 and post: 
2.3%, n=6; P<0.001). Of those patients who received an ABT, 
there was a significant increase in the number of patients 
receiving only a single unit of blood as per the guidelines 
following the implementation (P<0.003). Iron infusions were 
not given to any of the patients in the preimplementation 
group compared to 4.5% (n=12) in the postimplementation 
group prior to surgery (P=0.001). The use of tranexamic acid 
improved significantly following implementation (pre: 65%, 
n=155; post: 93%, n=242; P<0.0001) (Table 3).
Discussion
Our results showed that significantly more patients were 
treated according to the PBMP guidelines in undergoing 
all the required preoperative blood tests following our 
implementation strategy. The postimplementation group 
received a more rigorous preoperative assessment, resulting 
in increased administration of iron infusions for severely 
iron deficient patients and therefore avoiding the habitual 
approach of unnecessary ABT.26,27 In addition, there was a 
significant increase in the rates of single-unit transfusions 
and a corresponding decrease in 2-unit transfusions when 
compared to the preimplementation group. Single-unit 
transfusion practice is an integral component of a PBMP, as 
it decreases waste and risk associated with transfusions from 
multiple donors. In comparison, transfusions using 2 units of 
blood have often been a default decision without supportive 
empirical data, noncognizant of the risks versus the benefit.24 
In addition, the significant increase postimplementation in 
the use of antifibrinolytic agents such as tranexamic acid 
may have also contributed to the decrease in ABT due to 
their effects of reduction in blood loss and higher postop-
erative hemoglobin.28 These results are notable despite the 
significant number of patients with an ASA 3 score (severe 
systemic disease) in the postimplementation group compared 
to the preimplementation group, demonstrating the benefits 
of changing clinician behavior when treating patients with 
known comorbidities.
For those patients identified as anemic and/or iron defi-
cient, iron infusions were advocated instead of iron taken 
orally, as per the guidelines for those whose surgery is to 
commence within 2 months. Iron infusions are a more effec-
tive treatment for iron deficiency anemia because they correct 
levels more quickly than oral iron.10,29,30 The iron infusion can 
take effect between 2 and 6 weeks compared to oral intake that 
can require on average 6 weeks.31 Consequently, as our pri-
mary outcome was only relevant to patients 0–28 days prior 
to surgery, we did not collect data on the number of patients 
taking oral iron. Patients in the preimplementation group 
could not be identified as iron deficient due to lack of routine 
iron studies testing undertaken at that time. Therefore, none 
of the preimplementation group patients received an infusion 
Table 3 Patient preoperative diagnosis of anemia and iron deficiency and postoperative management
 Preimplementation 
(n=239) n (%)
Postimplementation 
(n=261) n (%)
P-value*
Preoperative anemia and iron deficiencya
Patients with anemia (full blood count – hemoglobin) 12 (5.0) 20 (7.6) 0.224
Patients with iron deficiency (full iron studies) Not known 105 (40)
Patients with anemia and iron deficiency (full blood count 
and full iron studies)
Not known 13 (4.9)
Iron infusion and intraoperative tranexamic acid injection
Received iron infusion preoperatively 0 12 (4.5) 0.001*
Tranexamic acid used, intraoperatively/postoperatively 155 (65) 242 (93) <0.0001*
Postoperative ABT
Number of patients who received an ABT 22 (9.2) 6 (2.3) 0.001*
1 blood unit 3/22 (14) 5/6 (83) 0.003a
2 blood units 16/22 (73) 1/6 (17) 0.022a
3–5 blood units 3/22 (14) 0/6 0.999a
Number of preoperative anemic patients (full blood count – 
hemoglobin) transfused
7/12 (58) 5/20 (25) 0.059
Number of patients with both preoperative anemia and iron 
deficiency transfused, as % of total patients transfused
Not known 4 (67) N/A
Notes: *P-value significant <0.05, aFisher’s exact test. Anemia defined as hemoglobin level of <130 g/L in men and <120 g/L in women; iron deficiency defined as ferritin level 
of <100 µg/L.21
Abbreviations: ABT, allogenic blood transfusion; N/A, not applicable.
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prior to surgery. That a significant increase of 4 days between 
the preoperative blood tests to day of surgery was observed 
is of note. This increase postimplementation allowed more 
time for further assessment of patients for anemia and/or 
iron deficiency and for treatment with iron infusion prior 
to surgery. It is possible some of these infusions also may 
have been ordered by the anesthetist (and not necessarily the 
surgeon) at the time of the preadmission clinic.
A limitation of our study is the time frame between 
audits. Prior to the PBM guidelines release at the end of 
2012, awareness of blood management among hospital 
clinicians was poor. Therefore, the decision for our study 
was to use the final 6 months of 2012 with the rationale that 
staff would be relatively untainted from the release of the 
PBM guidelines. This resulted in the time frame gap that 
is observed between the medical record audits for the pre- 
and postimplementation. We also did not collect data on the 
cost-effectiveness of our intervention, which was beyond the 
scope of our study.
The inherent challenges of implementation in a private 
hospital setting are of note. Australia has a growing private 
hospital sector operating alongside public hospitals. Private 
hospitals allow the medical practitioners more autonomy.32 
Therefore, private hospitals must balance the introduction of 
best practice guidelines without dictating this to medical staff. 
The preadmission clinic has a rapid flow of patients which 
discourages analytical review of pathology test results. The 
difficulty of obtaining a medical order in the private system 
and the potential for adverse side effects were contribut-
ing factors in the hesitation to prescribe an iron infusion. 
Although orthopedic surgeons at the hospital were aware of 
the advantages of meticulous surgical care and tranexamic 
acid use to reduce blood loss, they were less convinced about 
the importance of managing preoperative anemia and iron 
deficiency. Hence, although challenging, we successfully 
modified the surgeons’ views that a PBMP would be ben-
eficial for their medical reputation and better outcomes for 
their patients. To the best of our knowledge, this is one of the 
first published studies implementing the PBM guidelines in 
a private hospital setting in Australia.
Conclusion
Our results demonstrated that programs to implement guide-
lines can be built into the current processes of care and can 
improve patient outcomes. Our study is one of the few to 
provide evidence of the effectiveness of a targeted imple-
mentation to improve early assessment and preoperative 
management of anemia and/or iron deficiency in a private 
hospital setting. Other hospitals should consider replicating 
our intervention to better manage postoperative anemia and 
reduce the associated inherent risks of blood transfusions 
and conserving this limited resource.
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